Professor Anne Kiltie
MA DM DSc MRCP(UK) FRCR
Clinical Chair in Oncology
I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.
I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.
My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
- DSc Medical Sciences2016 - University of Oxford
- DM Medical Sciences1999 - University of Oxford
- BM BCh Medicine1988 - University of Oxford
- BA Medical Sciences1985 - University of Cambridge
- MRCP(UK) General Medicine1992 - Royal College of Physicians of England
- FRCR Clinical Oncology1995 - Royal College of Radiologists
- MA Medicine1989 - University of Cambridge
- MA Medicine1999 - University of Oxford
Memberships and Affiliations
- Internal Memberships
Jul 2021 - present Member of the Rowett Institute Ethics Panel
Oct 2021 - present Member of Friends of ANCHOR Research Advisory Group
- External Memberships
Jan 2022 - present Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022
Jan 2022 - present Member of Scottish Radiotherapy Research Forum committee
Oct 2018 - present Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Network Management Committee
Dec 2017 - present Member of Editorial Board of European Urology Oncology
Oct 2016 - present Associate Editor of Bladder Cancer
2014 - present Grant reviewer for Italian Association for Cancer Research (AIRC)
Sept 2012 - present British Uro-oncology Group Executive Committee Trustee
Jan 2012 - present Royal College of Radiologists representative on Advisory Appointments Committees
Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.
Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Applied Health Sciences
Nutrition and Health
ME3013 MBChBSSC2: supervisor
BM4501 BSc Honours project: supervisor
RN5505 Clinical Nutrition: lecture and seminar
RN5503 Clinical Nutrition for Disease Prevention: lecture
Non-course Teaching Responsibilities
I am a Regent for the MB ChB Regent Scheme.
Supervised Daniel Sescu, Cyril and Margaret Gates Trust ASRS summer scholarship
Page 1 of 10 Results 1 to 10 of 91
Immunofluorescence microscopy-based detection of ssDNA foci by BrdU in mammalian cellsSTAR Protocols, vol. 2, no. 4, 100978Contributions to Journals: Articles
The role of dietary supplements, including biotics, glutamine, polyunsaturated fatty acids and polyphenols, in reducing gastrointestinal side effects in patients undergoing pelvic radiotherapy: A systematic review and meta-analysisClinical and Translational Radiation Oncology, vol. 29, pp. 11-19Contributions to Journals: Articles
Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and MicrobubblesUltrasound in Medicine and Biology, vol. 47, no. 6, pp. 1596-1615Contributions to Journals: Articles
p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiationCell Reports, vol. 35, no. 8, 109153Contributions to Journals: Articles
Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer ModelInternational Journal of Radiation Oncology Biology Physics, vol. 109, no. 5, pp. 1472-1482Contributions to Journals: Articles
SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cellsCell Death and Disease, vol. 12, no. 2, 165Contributions to Journals: Articles
Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancerJournal of Pathology: Clinical Research, vol. 6, no. 4, pp. 238-251Contributions to Journals: Articles
Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisationBMC Biology, vol. 18, 102Contributions to Journals: Articles
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in VivoInternational Journal of Radiation Oncology Biology Physics, vol. 107, no. 1, pp. 212-221Contributions to Journals: Articles
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines CommitteesEuropean Urology, vol. 77, no. 2, pp. 223-250Contributions to Journals: Articles